Columbia Threadneedle’s Corporate Income Fund returned 2.05% in Q2 2025 amid market volatility and tariff shocks. Explore how ...

The most likely range for 3-month bill yields falls to the 1% to 2% range within 30 months, according to this week’s ...

The S&P 500 made a fresh new ATH last week, but I think the news is that small-cap stocks are finally starting to perform, ...

Columbia Threadneedle’s Convertible Securities Fund beat its benchmark in Q2 2025, fueled by tech and crypto-linked ...

XONE offers low-cost, short-duration Treasury exposure, making it attractive for those seeking limited duration risk. See why ...

Suzano maintains a strong cost advantage in pulp production, exporting to stable and growing markets, creating a solid moat ...

Columbia Threadneedle’s Contrarian Core Fund beat its benchmark in Q2 2025 amid AI-fueled tech gains. Explore what drove ...

Discover a balanced SPG investment analysis considering fundamentals, investor psychology, and personal factors.

Gilead Sciences' valuation exceeds fundamentals, prompting a SELL recommendation. Discover why this $150B biopharma stock may ...

Columbia Threadneedle’s Bond Fund beat its benchmark in Q2 2025 with smart duration and credit picks. See how it navigated ...

Schlumberger is undervalued vs. peers, with ChampionX synergies, solid financials, and segment growth offsetting risks. Find ...

The pan-European Stoxx 600 ( STOXX) ticked 0.1% lower on Monday as investors traded with caution ahead of President Trump's meeting with Ukrainian President Volodymyr Zelenskyy and European leaders in ...